title: CD23 antigen density is related to serum gamma globulin level, bone marrow reticulin pattern, and treatment in B chronic lymphocytic leukemia.
abstract: The CD23 antigen density was evaluated by a cytofluorometric technique in 55 patients with chronic lymphocytic leukemia. The quantification method was based on the use of biological standards in indirect immunofluorescence. The CD23 antigen density was correlated with the percentage of CD23 positive cells, but antigen density appeared to be a more informative parameter. CD23 antigen density was lower in stage B than in stages A or C patients, and higher in patients undergoing chemotherapy or previously treated than in untreated patients. There was a significant negative correlation between CD23 antigen density and serum gamma globulin and IgG levels, that existed only in patients in an advanced stage of the disease. CD23 antigen density was higher in patients with abnormal bone marrow reticulin pattern. Serum gamma globulin level was lower in these patients, as well as in patients with prognostically unfavorable histologic bone marrow infiltration pattern. These data emphasize the interest of antigen density as an additional parameter and the complex relationship between CD23 expression, hypogammaglobulinemia, bone marrow histologic findings, and treatment in chronic lymphocytic leukemia.
authors.affiliation: Service des Maladies du Sang, Hôpital Lapeyronie, Montpellier, France.
authors.forename: T
authors.initials: T
authors.lastname: Lavabre-Bertrand
authors.forename: C
authors.initials: C
authors.lastname: Exbrayat
authors.forename: P
authors.initials: P
authors.lastname: Bourquard
authors.forename: C
authors.initials: C
authors.lastname: Lavabre-Bertrand
authors.forename: N
authors.initials: N
authors.lastname: Fégueux
authors.forename: P
authors.initials: P
authors.lastname: Poncelet
authors.forename: T
authors.initials: T
authors.lastname: Rousset
authors.forename: J
authors.initials: J
authors.lastname: Taïb
authors.forename: J M
authors.initials: JM
authors.lastname: Emberger
authors.forename: M
authors.initials: M
authors.lastname: Navarro
mesh_terms: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D005455:Fluorescent Antibody Technique; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood* / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage; D017455:Receptors, IgE / Q000032:analysis*; D012155:Reticulin / Q000032:analysis*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage; D005719:gamma-Globulins / Q000032:analysis*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D017455:Receptors, IgE; D012155:Reticulin; D005719:gamma-Globulins; D002699:Chlorambucil; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D014740:Vidarabine; C024352:fludarabine